BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 15788643)

  • 21. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.
    Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A
    J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The chromogranin-A (CgA) in prostate cancer.
    Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
    Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
    Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
    J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
    Sciarra A; Di Silverio F; Autran AM; Salciccia S; Gentilucci A; Alfarone A; Gentile V
    Urol Int; 2009; 82(2):147-51. PubMed ID: 19321999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer.
    Reis LO; Vieira LF; Zani EL; Denardi F; de Oliveira LC; Ferreira U
    J Investig Med; 2010 Dec; 58(8):957-60. PubMed ID: 20818262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.
    Wu JT; Erickson AJ; Tsao KC; Wu TL; Sun CF
    Ann Clin Lab Sci; 2000 Apr; 30(2):175-8. PubMed ID: 10807161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroendocrine differentiation in stage D2 prostate cancers.
    Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
    Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.
    Puccetti L; Supuran CT; Fasolo PP; Conti E; Sebastiani G; Lacquaniti S; Mandras R; Milazzo MG; Dogliani N; De Giuli P; Fasolis G
    Eur Urol; 2005 Aug; 48(2):215-21; Discussion 221-3. PubMed ID: 15992991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Study of the hormone-refractory prostate cancer clinical practice in an anti-cancer center].
    Zufferey L; Roques B; Fléchon A; Droz JP
    Bull Cancer; 2001 Dec; 88(12):1213-21. PubMed ID: 11792613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma.
    Hotte SJ; Winquist EW; Stitt L; Wilson SM; Chambers AF
    Cancer; 2002 Aug; 95(3):506-12. PubMed ID: 12209742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma.
    Cipolla BG; Ziade J; Bansard JY; Moulinoux JP; Staerman F; Quemener V; Lobel B; Guillé F
    Cancer; 1996 Sep; 78(5):1055-65. PubMed ID: 8780544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
    Petrioli R; Rossi S; Caniggia M; Pozzessere D; Messinese S; Sabatino M; Marsili S; Correale P; Salvestrini F; Manganelli A; Francini G
    Urology; 2004 Feb; 63(2):321-6. PubMed ID: 14972482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer.
    Gandhok NK; Looney S; Koochekpour S; Sartor O
    Urol Oncol; 2005; 23(3):163-7. PubMed ID: 15907715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum chromogranin A in monitoring metastatic prostate cancer patients.
    Tarle M
    Anticancer Res; 1999; 19(6C):5663-6. PubMed ID: 10697637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.
    George DJ; Halabi S; Shepard TF; Sanford B; Vogelzang NJ; Small EJ; Kantoff PW
    Clin Cancer Res; 2005 Mar; 11(5):1815-20. PubMed ID: 15756004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
    May M; Siegsmund M; Hammermann F; Loy V; Gunia S
    Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
    Okegawa T; Kinjo M; Nutahara K; Higashihara E
    Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.
    Berruti A; Tucci M; Mosca A; Tarabuzzi R; Gorzegno G; Terrone C; Vana F; Lamanna G; Tampellini M; Porpiglia F; Angeli A; Scarpa RM; Dogliotti L
    Br J Cancer; 2005 Sep; 93(6):633-8. PubMed ID: 16222309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.